<i>CYP2C19</i> Phenotype, P2Y₁₂ Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy.

ABSTRACT:

Background

Use of CYP2C19 genotyping to guide antiplatelet therapy is associated with improved clinical outcomes in patients naïve to P2Y₁₂ inhibitors undergoing percutaneous coronary intervention. The relationship between CYP2C19 genotype and clinical outcomes in patients on maintenance clopidogrel at the time of percutaneous coronary intervention is unknown.

Methods

This was a retrospective, multicenter cohort study. Patients were characterized as intermediate or poor metabolizers versus normal or rapid or ultrarapid metabolizers on the basis of CYP2C19 genotype. Major adverse cardiovascular events included cardiovascular death, myocardial infarction, ischemic stroke, or stent thrombosis.

Results

The study population (N=4246) had a me

SUBMITTER: Patel RC 

PROVIDER: S-EPMC12533675 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature